medigraphic.com
Órgano de Difusión de la Asociación Académica Panamericana de Medicina Familiar A.C.

2023, Número 2

<< Anterior Siguiente >>

Arch Med Fam 2023; 25 (2)


Papel de las estatinas en el manejo del COVID 19

Rubio GAF, Narvaez OGI

Idioma: Español
Referencias bibliográficas: 28
Paginas: 97-101
Archivo PDF: 213.54 Kb.


RESUMEN

Las estatinas son fármacos que se desarrollaron para el manejo de las dislipidemias, sin embargo, se han descrito otros efectos de las mismas, a los que se les ha llamado pleiotrópico, destacando su efecto antiinflamatorio y modificador de los niveles de diversas citoquinas, dentro de los efectos pleiotrópicos se ha descrito actividad antiviral. En esta revisión, buscamos en PubMed información sobre estatinas en infecciones virales en general, y en infección por COVID-19 en particular, analizando la información más reciente tanto su posible papel en la profilaxis, así como en el tratamiento de la enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Rubio-Guerra AF. Hipertensión arterial, sistema renina angiotensinaaldosterona e infección por Covid-19. En Castro-Martínez G, RubioGuerra AF. Diabetes y Corazón. México, Alfil, 2021. 237-244.

  2. Surma S, Banach M, Lewek J. COVID-19 and lipids. The role of lipiddisorders and statin use in the prognosis of patients with SARSCoV-2 infection. Lipids Health Dis. 2021;20:141.

  3. Kollias A, Kyriakoulis KG, Kyriakoulis IG, Nitsotolis T, Poulakou G,Stergiou GS, et al. Statin use and mortality in COVID-19 patients:Updated systematic review and meta-analysis. Atherosclerosis.2021;330:114-121.

  4. Lee HY, Ahn J, Park J, Kyung Kang C, Won SH, Wook Kim D, et al.Korean Society of Hypertension, National Committee for ClinicalManagement of Emerging Infectious Diseases. Beneficial Effectof Statins in COVID-19-Related Outcomes-Brief Report: A NationalPopulation-Based Cohort Study. Arterioscler Thromb Vasc Biol. 2021;41:e175-e182.

  5. de Pádua Borges R, Degobi NAH, Bertoluci MC. Choosing statins:a review to guide clinical practice. Arch Endocrinol Metab.2020;64:639-653

  6. Fedson DS, Rordam OM. Treating Ebola patients: a ‘bottom up’approach using generic statins and angiotensin receptor blockers.Int J Infect Dis. 2015;36:80-4.

  7. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, et al.Prior statin therapy is associated with a decreased rate of severesepsis. Circulation. 2004;110:880-885.

  8. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins onmortality in patients with bacteremia. Clin Infect Dis. 2001;33:1352-1357.

  9. Gorabi AM, Kiaie N, Bianconi V, Jamialahmadi T, Al-Rasadi K,Johnston TP, et al. Antiviral effects of statins. Prog Lipid Res.2020;79:101054.

  10. Kwong JC, Li P, Redelmeier DA. Influenza morbidity and mortalityin elderly patients receiving statins: a cohort study. PLoS One.2009;4:e8087.

  11. Wu BR, Chen DH, Liao WC, et al. Statin Therapy and the Risk of ViralInfection: A Retrospective Population-Based Cohort Study. J ClinMed. 2022;11:5626. doi:10.3390/jcm11195626

  12. Liao Z, Cimakasky LM, Hampton R, Nguyen DH, Hildreth JE.Lipid rafts and HIV pathogenesis: host membrane cholesterol isrequired for infection by HIV type 1. AIDS Res Hum Retroviruses.2001;17:1009-1019.

  13. Gower TL, Graham BS. Antiviral activity of lovastatin againstrespiratory syncytial virus in vivo and in vitro. Antimicrob AgentsChemother. 2001;45:1231-7

  14. Rothwell C, Lebreton A, Young Ng C, Lim JY, Liu W, Vasudevan S,et al. Cholesterol biosynthesis modulation regulates dengue viralreplication. Virology. 2009;389:8-19.

  15. Shrivastava-Ranjan P, Flint M, Bergeron É, McElroy AK, Chatterjee P,Albariño CG, et al. Statins Suppress Ebola Virus Infectivity by Interferingwith Glycoprotein Processing. mBio. 2018;9:e00660-18.

  16. Martínez-Gutierrez M, Castellanos JE, Gallego-Gómez JC. Statinsreduce dengue virus production via decreased virion assembly.Intervirology. 2011;54:202-216.

  17. Gilbert C, Bergeron M, Méthot S, Giguère JF, Tremblay MJ. Statinscould be used to control replication of some viruses, including HIV-1. Viral Immunol. 2005;18:474-89.

  18. Rubio-Guerra AF, Vargas-Robles H, Vargas-Ayala G, Rodríguez-LópezL, Elizalde-Barrera CI, Escalante-Acosta BA. The Lipid IndependentEffect of Statins on Albuminuria in Type-2 Diabetes Mellitus. JCvD2014;2:143-146.

  19. Lima Martínez MM, Contreras MA, Marín W, D’Marco L. Estatinasen COVID- ¿existe algún fundamento?. Clin Investig Arterioscler.

  20. 2020;32:278-281.20. Vuorio A, Kovanen PT. Statins as Adjuvant Therapy for COVID-19 toCalm the Stormy Immunothrombosis and Beyond. Front Pharmacol.2021 Jan 19;11:579548.

  21. Kow C. S., Hasan S. S. Meta-analysis of effect of statins in patientswith COVID-19. Am. J. Cardiol.2020;134:153–155.

  22. Daniels LB, Ren J, Kumar K, Bui QM, Zhang J, Zhang X, et al. Relationof prior statin and anti-hypertensive use to severity of diseaseamong patients hospitalized with COVID-19: Findings from the AmericanHeart Association’s COVID-19 Cardiovascular Disease Registry.PLoS One. 2021 Jul 15;16(7):e0254635

  23. Lohia P, Kapur S, Benjaram S, Mir T. Association betweenantecedent statin use and severe disease outcomes in COVID-19:A retrospective study with propensity score matching. J ClinLipidol. 2021;15:451-459.

  24. Bouillon K, Baricault B, Semenzato L, Botton J, Bertrand M, DrouinJ, et al. Association of Statins for Primary Prevention of CardiovascularDiseases With Hospitalization for COVID-19: A NationwideMatched Population-Based Cohort Study. J Am Heart Assoc. 2022Jun 21;11(12):e023357.

  25. Lee HY, Ahn J, Park J, Kyung Kang C, Won SH, Wook Kim D, et al.Korean Society of Hypertension, National Committee for ClinicalManagement of Emerging Infectious Diseases. Beneficial Effectof Statins in COVID-19-Related Outcomes-Brief Report: A NationalPopulation-Based Cohort Study. Arterioscler Thromb Vasc Biol.2021;41:e175-e182.

  26. Barge-Caballero E, Marcos-Rodríguez PJ, Domenech-García N,Bou-Arévalo G, Cid-Fernández J, Iglesias-Reinoso R, et al. Survivalimpact of previous statin therapy in patients hospitalized withCOVID-19. Med Clin (Barc). 2022 May 8:S0025-7753(22)00189-0.English, Spanish. doi: 10.1016/j.medcli.2022.03.015. Epub ahead ofprint. PMID: 35618499; PMCID: PMC9080058

  27. Andrews L, Goldin L, Shen Y, Korwek K, Kleja K, Poland RE, et al.Discontinuation of atorvastatin use in hospital is associated withincreased risk of mortality in COVID-19 patients. J Hosp Med. 2022Mar;17(3):169-175.

  28. Xu E, Xie Y, Al-Aly Z. Risks and burdens of incident dyslipidaemiain long COVID: a cohort study. Lancet Diabetes Endocrinol.2023;11:120-128. doi:10.1016/S2213-8587(22)00355-2




2020     |     www.medigraphic.com